Trimebutine
Chemical compound
- A03AA05 (WHO)
- 2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoate
- 39133-31-8
Y
- 5573
- 5372
N
- QZ1OJ92E5R
- ChEMBL190044 N
- DTXSID4023707
- Interactive image
- CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C
InChI
- InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3N
- Key:LORDFXWUHHSAQU-UHFFFAOYSA-NN
N
Y (what is this?) (verify)Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.[1] It is used for the treatment of irritable bowel syndrome and other gastrointestinal disorders.
The major product from drug metabolism of trimebutine in human beings is nortrimebutine,[2] which comes from removal of one of the methyl groups attached to the nitrogen atom. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract.[3]
Both trimebutine and its metabolite[citation needed] are commercially available.
Brand names
The maleic acid salt of trimebutine is marketed under the trademarks of Antinime, Cineprac, Colospasmyl, Colypan, Crolipsa, Debricol, Debridat, Digedrat, Espabion, Gast Reg, Irritratil, Krisxon, Muttifen, Neotina, Polybutin,[4] Sangalina, Trebutel, Tribudat, Tributina, Trim, Trimeb, Trimedat, and Trimedine.
See also
References
- ^ Kaneto H, Takahashi M, Watanabe J (July 1990). "The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies". Journal of Pharmacobio-Dynamics. 13 (7): 448–53. doi:10.1248/bpb1978.13.448. hdl:10069/38849. PMID 1963196.
- ^ Roman FJ, Lanet S, Hamon J, Brunelle G, Maurin A, Champeroux P, et al. (June 1999). "Pharmacological properties of trimebutine and N-monodesmethyltrimebutine". The Journal of Pharmacology and Experimental Therapeutics. 289 (3): 1391–7. PMID 10336531.
- ^ Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K (April 2009). "Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract" (PDF). Journal of Gastroenterology and Hepatology. 24 (4): 537–46. doi:10.1111/j.1440-1746.2009.05780.x. PMID 19220673. S2CID 25767036.
- ^ Jhee OH, Lee YS, Shaw LM, Jeon YC, Lee MH, Lee SH, Kang JS (January 2007). "Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC-MS/MS method". Clinica Chimica Acta; International Journal of Clinical Chemistry. 375 (1–2): 69–75. doi:10.1016/j.cca.2006.06.006. PMID 16854404.
- v
- t
- e
Drugs for functional gastrointestinal disorders (A03)
functional
bowel
disorders
| Antimuscarinics |
| ||||
|---|---|---|---|---|---|
| Phosphodiesterase inhibitors | |||||
| Acting on serotonin receptors |
| ||||
| Other |
and derivatives
(antimuscarinics)
- Tertiary amines: Atropine
- Hyoscyamine
- Quaternary ammonium compounds:
- Methylatropine
- Fentonium bromide
- Cimetropium bromide
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
